[18F]FDG and [18F]FES PET/CT Imaging for Predicting Response to Rintodestrant in Patients With Metastatic ER+ Breast Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Clinical Cancer Research
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
[18F]FDG and [18F]FES PET/CT Imaging as a Biomarker for Therapy Effect in Patients with Metastatic ER+ Breast Cancer Undergoing Treatment with Rintodestrant
Clin. Cancer Res 2023 Feb 03;[EPub Ahead of Print], R Iqbal, M Yaqub, HO Bektas, DE Oprea-Lager, EGE de Vries, AWJM Glaudemans, P Aftimos, G Gebhart, AP Beelen, RC Schuit, AD Windhorst, R Boellaard, CW Menke-van der Houven van OordtFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.